Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 513 is a nuclear transcription factor with critical roles in the regulation of photoreceptor-specific genes during retinal development and maintenance. It binds to promoters of genes necessary for photoreceptor differentiation and survival, such as Pax6, Sp4, Arr3, Irbp, and photoreceptor opsins. Mutations in ZNF513, especially c.1015T>C (p.C339R), cause a form of autosomal-recessive retinitis pigmentosa manifesting as progressive photoreceptor degeneration, decreased retinal thickness, and loss of vision. ZNF513 is mainly expressed in retinal tissue, particularly the outer and inner nuclear layers and photoreceptors, and is essential for gene regulatory networks governing visual function. No direct therapeutics or interacting drugs are in clinical use or investigation, and current evidence focuses on understanding ZNF513’s pathogenic mutations and their mechanistic links to inherited retinal diseases.
Not established or reported for drugs, as ZNF513 is not targeted by any approved therapies
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 513 (ZNF513).